Goldman Sachs Group set a €86.00 ($100.00) target price on MorphoSys (ETR:MOR) in a research report released on Wednesday, September 26th. The firm currently has a neutral rating on the stock.

MOR has been the topic of a number of other research reports. Commerzbank set a €107.00 ($124.42) price target on MorphoSys and gave the company a neutral rating in a report on Wednesday, August 22nd. Deutsche Bank set a €120.00 ($139.53) price target on MorphoSys and gave the company a neutral rating in a report on Monday, August 6th. Berenberg Bank set a €103.00 ($119.77) price target on MorphoSys and gave the company a buy rating in a report on Thursday, August 2nd. HSBC set a €56.00 ($65.12) price target on MorphoSys and gave the company a sell rating in a report on Tuesday, August 14th. Finally, Independent Research set a €110.00 ($127.91) price target on MorphoSys and gave the company a neutral rating in a report on Friday, July 6th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. MorphoSys has a consensus rating of Hold and an average price target of €95.80 ($111.40).

Shares of MOR traded up €1.10 ($1.28) during trading hours on Wednesday, hitting €81.45 ($94.71). The company had a trading volume of 300,197 shares, compared to its average volume of 153,687. MorphoSys has a 52-week low of €49.63 ($57.71) and a 52-week high of €88.10 ($102.44).

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Recommended Story: Return on Equity (ROE)

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.